Back to News
Market Impact: 0.25
Ascendis, BioMarin Enter Global Settlement, License Deal For YUVIWEL; Ascendis Stock Up
Source: Nasdaq
Legal & LitigationM&A & RestructuringCompany Fundamentals
Ascendis Pharma (ASND) entered into a binding term sheet with BioMarin (BMRN) for a global settlement and license agreement covering YUVIWEL (navepegritide) and related products. The agreement structure suggests resolution of disputes and continued commercialization via licensing, which is generally supportive for both parties. Specific financial terms and timing were not provided in the excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ASND0.55
BMRN0.35
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’